MONTREAL,
April 19,
2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB:
VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo's Chief Executive Officer,
will present a corporate overview and provide a commercial update
on key products of the Company at the 2023 Bloom Burton & Co
Healthcare Investor Conference.
Presentation Details:
|
Event:
|
2023 Bloom Burton &
Co. Healthcare Investor Conference
|
|
Date/Time:
|
Tuesday, April 25, 2023
at 11:00 am ET
|
A live webcast of the presentation may be
accessed via
https://wsw.com/webcast/bloomburton8/vph/2543354 and on the
Webcast & Events page under the Investors section of the
Company's website at Events - Valeo Pharma. Following the event, an
archived webcast will be available on the Company's website.
About the Conference:
The Bloom Burton & Co. Healthcare Investor
Conference brings together U.S., Canadian and international
investors who are interested in the latest developments in the
Canadian healthcare sector. Attendees will have an opportunity to
obtain corporate updates from the premier Canadian publicly traded
and private companies through presentations and private
meetings.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the necessary capabilities and a complete
infrastructure to register and manage its growing product portfolio
through all stages of commercialization. For more information,
please visit www.valeopharma.com and follow us on LinkedIn and
Twitter.
Forward Looking
Statements
This press release contains forward-looking
statements about Valeo's objectives, strategies and businesses that
involve risks and uncertainties. These statements are
"forward-looking" because they are based on our current
expectations about the markets we operate in and on various
estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our
estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.